The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy
Abstract
In a large population‐based case–control study in Germany, including 3,464 breast cancer cases aged 50–74 at diagnosis and 6,657 population based and frequency matched controls, we investigated the effects of menopausal hormone therapy (HT) by type, regimen, timing and progestagenic constituent on postmenopausal breast cancer risk overall and according to histological type. Data were collected by face‐to‐face interviews. Logistic and polytomous logistic regression analysis were used to estimate odds ratios (OR) and 95%‐confidence intervals (95% CI). Risk of invasive breast cancer was significantly elevated in current users (OR, 1.73, 95% CI, 1.55–1.94) and heterogeneous by histological type (p < 0.01), being more than 2‐fold higher for lobular and tubular than for ductal cancer. Risks for current users varied significantly by type and regimen of HT, with ORs per year of use of 1.05 (95% CI, 1.04–1.06) for continuous combined estrogen–progestagen, 1.03 (95% CI, 1.02–1.04) for cyclical EP and 1.01 (95% CI, 1.00–1.03) for estrogen‐only therapy. No statistically significant increase in risk was observed after 5 years of cessation of HT use for any histological type. Analyses of progestagenic content by regimen revealed a significantly higher risk for continuously administered norethisterone‐ or levonorgestrel‐derived progestagens than for continuously administered progesterone‐derived progestagens (OR, 2.27, 95% CI, 1.98–2.62 vs. 1.47, 95% CI, 1.12–1.93, respectively, p = 0.003), which may be explained by dose rather than type of progestagen. These data suggest that the risks associated with menopausal HT differ by type and regimen of HT and histological type of breast cancer and may vary by progestagenic component, depending on the effective dose. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487 · cited 1×
“The higher risk associated with EP therapy compared to mono-estrogen therapy has also been observed across different histological tumor types.(6,17,18) Several studies have investigated differences in risk by regimen, however, a higher risk for continuous than for cyclical EP therapy was found only in Scandinavian stu…”
Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin
Ross, R. K. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.4.328 · Cited by 877
Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9523-x · Cited by 693
Cited by
Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H., Milne, R. L., Gaudet, M., Schmidt, M. K., Broeks, A., Cox, A., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq526 · Cited by 691
Self-citationMicroRNA Related Polymorphisms and Breast Cancer Risk
Khan, S., Greco, D., Michailidou, K., Milne, R. L., Muranen, T. A., Heikkinen, T., Aaltonen, K., Dennis, J., Bolla, M. K., Liu, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109973 · Cited by 638
Self-citationNight work and breast cancer – results from the German GENICA study
Pesch, B., Harth, V., Rabstein, S., Baisch, C., Schiffermann, M., Pallapies, D., Bonberg, N., Heinze, E., Spickenheuer, A., Justenhoven, C., et al. (2010) · Scandinavian Journal of Work, Environment & Health · doi:10.5271/sjweh.2890 · Cited by 132
Zaineddin, A. K., Buck, K., Vrieling, A., Heinz, J., Flesch-Janys, D., Linseisen, J., & Chang-Claude, J. (2012) · Nutrition and Cancer · doi:10.1080/01635581.2012.683227 · Cited by 90
Self-citationRudolph, A., Hein, R., Lindström, S., Beckmann, L., Behrens, S., Liu, J., Aschard, H., Bolla, M. K., Wang, J., Truong, T., et al. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0349 · Cited by 28
Self-citation
Metadata
- Authors
- Flesch‐Janys, D., Slanger, T., Mutschelknauss, E., Kropp, S., Obi, N., Vettorazzi, E., Braendle, W., Bastert, G., Hentschel, S., Berger, J., & Chang‐Claude, J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2008-06-12
- Volume
- 123
- Issue
- 4
- Pages
- 933-941
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1535819521
- Cited by
- 171
- References
- 4
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. https://app.cochat.ai/papers/10.1002/ijc.23655
- The paper
- Flesch‐Janys, D., Slanger, T., Mutschelknauss, E., Kropp, S., Obi, N., Vettorazzi, E., Braendle, W., Bastert, G., Hentschel, S., Berger, J., & Chang‐Claude, J. (2008). Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.23655
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.